LAX.SH
INDEGENE LIMITED·Healthcare Companies·Healthcare Services Companies
Price
588.1
+1.3%52W Range
Market Cap
₹14,171.25 Cr
Traded: ₹22.94 Cr (0.16%) 0.0x
Free Float: ₹9,579.77 Cr (0.24% of FF traded)
Volume · 60D trend
3.92 L 0.0x
Delivery: % 0.0x
View Delivery Data
Returns
RS Score
Create a free account to unlock your edge
Scanners, market pulse, FII/DII data, and TradingView charts — free forever
Valuation
Business Strength
Growth (3Y CAGR)
Balance Sheet
Cash Position
Others
MTF Exposure Trend
60 sessions · funded amount, % of FF, daily delta
LAX.SH
Growth Trends
| Metric | 10Y | 5Y | 3Y | 1Y | TTM | Trend |
|---|---|---|---|---|---|---|
| ROE | -- | +21.0% | +19.0% | -- | -- | Decelerating |
| Return | -- | -- | -- | -9.0% | -- | -- |
| Sales | -- | +29.0% | +15.0% | -- | +24.0% | Stable |
| Profit | -- | +23.0% | +16.0% | -- | +0.0% | Decelerating |
Quarterly Results
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Revenue & Margin Trends
Annual
Quarterly
Balance Sheet Health
Leverage
Efficiency
Cash Position
Detailed Financials
Jun 2026PDF ↗ | Mar 2026PDF ↗ | Dec 2025PDF ↗ | Sep 2025PDF ↗ | Jun 2025PDF ↗ | Mar 2025PDF ↗ | Dec 2024PDF ↗ | Sep 2024PDF ↗ | Jun 2024PDF ↗ | Mar 2024PDF ↗ | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,063 | 1,003 | 942 | 804 | 761 | 756 | 720 | 687 | 676 | 673 | 673 | 636 | 608 | 632 |
| Expenses | 889 | 840 | 783 | 664 | 606 | 608 | 589 | 561 | 548 | 534 | 524 | 515 | 511 | 535 |
| Operating Profit | 174 | 164 | 160 | 141 | 155 | 148 | 132 | 126 | 129 | 139 | 149 | 121 | 97 | 97 |
| Other Income | 29 | -10 | 19 | 20 | 22 | 26 | 38 | 21 | 22 | 26 | 13 | 12 | 28 | 13 |
| Interest | 6 | 7 | 5 | 4 | 4 | 3 | 3 | 4 | 12 | 12 | 12 | 12 | 13 | 12 |
| Depreciation | 44 | 42 | 40 | 23 | 22 | 21 | 20 | 19 | 20 | 18 | 18 | 20 | 20 | 20 |
| Profit Before Tax | 153 | 105 | 135 | 133 | 152 | 149 | 146 | 124 | 120 | 134 | 132 | 101 | 92 | 79 |
| Tax % | 24.0% | 24.0% | 24.0% | 23.0% | 23.0% | 21.0% | 25.0% | 26.0% | 27.0% | 29.0% | 25.0% | 25.0% | 26.0% | 38.0% |
| Net Profit | 116 | 80 | 103 | 102 | 116 | 118 | 110 | 92 | 88 | 95 | 99 | 75 | 68 | 49 |
| Exceptional Items | -- | -20 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| EPS (Rs) | 4.8 | 3.3 | 4.3 | 4.3 | 4.8 | 4.9 | 4.6 | 3.8 | 3.7 | 4.3 | 4.5 | 3.4 | 3.1 | 2.2 |
| Sales Growth (YoY) | -- | 32.8% | 30.8% | 17.1% | 12.5% | 12.3% | 7.0% | 8.0% | 11.4% | 6.5% | -- | -- | -- | -- |
| Sales Growth (QoQ) | -- | 6.5% | 17.2% | 5.7% | 0.7% | 5.0% | 4.8% | 1.6% | 0.5% | 0.0% | 5.8% | 4.6% | -3.8% | -- |
| OP Growth (YoY) | 12.3% | 10.8% | 21.2% | 11.9% | 20.2% | 6.5% | -11.4% | 4.1% | 33.0% | 43.3% | -- | -- | -- | -- |
| OP Growth (QoQ) | 6.1% | 2.5% | 13.5% | -9.0% | 4.7% | 12.1% | 4.8% | -2.3% | -7.2% | -6.7% | 23.1% | 24.7% | 0.0% | -- |
| Profit Growth (YoY) | -- | -19.0% | -6.0% | 11.0% | 33.0% | 26.0% | 11.0% | 22.0% | 28.0% | 91.0% | -- | -- | -- | -- |
| EPS Growth (YoY) | -- | -32.5% | -6.5% | 11.0% | 32.1% | 15.0% | 2.9% | 13.3% | 19.2% | 93.6% | -- | -- | -- | -- |
| EPS Growth (QoQ) | -- | -22.7% | 0.7% | -12.4% | -1.0% | 7.0% | 19.6% | 4.4% | -13.8% | -4.3% | 31.7% | 9.7% | 40.0% | -- |
| OP Margin | -- | 16.4% | 17.0% | 17.5% | 20.4% | 19.6% | 18.3% | 18.3% | 19.1% | 20.6% | 22.1% | 19.0% | 15.9% | 15.3% |
| Net Margin | -- | 8.0% | 10.9% | 12.7% | 15.2% | 15.6% | 15.3% | 13.4% | 13.0% | 14.1% | 14.7% | 11.8% | 11.2% | 7.8% |
| Material Cost % | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| Employee Cost % | -- | 63.0% | 60.0% | 64.0% | 63.0% | 64.0% | 62.0% | 64.0% | 66.0% | 64.0% | 61.0% | 64.0% | 67.0% | 66.0% |
| P/S | 3.72 | 3.53 | 3.66 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/E | 35.30 | 30.84 | 27.10 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
| P/B | 4.51 | 3.95 | 4.16 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- |
Exchange Filings
50Press Release
Resignation of Mr. Mark Francis Dzialga (DIN: 00955485) from the position of Non-Executive Non Independent Director of the Company
Certificate under Regulation 74 (5) of SEBI DP Regulations, 2018
Allotment of ESOP shares
Press Release
Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/10/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Intimation of Indegene Limited Q2 FY27 Earnings Call
Closure of Trading Window
Press Release
Disclosure under Regulation 30 of SEBI (LODR) Regulation, 2015 - Merger of Indirect Wholly owned subsidiaries of the Company in Germany
Intimation of Investors / Analysts Meeting
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly- Owned Subsidiary, Indegene, Inc.
Update on Material Litigation under the Telephone Consumer Protection Act, 1991 involving Wholly-Owned Subsidiary, Indegene, Inc.
Intimation of Investors / Analysts Meeting
Scrutinizer''s Report - 28th Annual General Meeting
Appointment of Ms. Jill Mary De Simone (DIN: 11483134) as an independent Director of the Company
Transcript of the 28th Annual General Meeting held on August 13, 2026
Intimation of Investors / Analysts Meeting
Proceedings of the 28th Annual General Meeting of the Company
Intimation of Investors / Analysts Meeting
Intimation of Investors / Analysts Meeting
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I SPV Ltd
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for BPC Genesis Fund I- A SPV Ltd
Unaudited Financial Results for the Quarter ended June 30, 2026
Intimation of Newspaper Publication
Notice of the 28th Annual General Meeting of the Company
Annual Report of the Company for financial year 2025-26
Business Responsibility and Sustainability Report for the financial year 2025-26
Letter to Shareholders in relation to Annual Report of the Company for the financial year 2025-26
Intimation of Newspaper Publication
Record date for payment of Final Dividend
Outcome of the Board Meeting held on July 15, 2026
Indegene Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/07/2026 ,inter alia, to consider and approve the Unaudited Standalone and Consolidated ....
Intimation of Indegene Limited Q1 FY27 Earnings Call
Certificate under Regulation 74(5) of SEBI DP Regulations, 2018
Closure of Trading Window
Intimation of Investors / Analysts Meeting
Revised Investor Presentation
Investor Presentation
Intimation of Investors / Analysts Meeting
Transcript of earnings conference call on financial results for the quarter and year ended March 31, 2026
Assessment order received under Section 143(3) read with 144C(3) read with 144B of the Income Tax Act, 1961 for the Assessment Year 2023-24(corresponding to the Financial Year 2022-23)
Press Release
Intimation of Newspaper Publication.
Audio Recording of the Q4 and Annual FY26 Earnings Call
Outcome of Board Meeting
Press Release
Analyst Presentation and fact sheet - financial results for the quarter and year ended March 31, 2026
<b>Format of Initial Disclosure to be made by an entity identified as a Large Corporate.</b><br/><br/> <table border=''1px''><tr> <td><b>Sr. No.</b></td> <td><b>Particulars</b></td> <td><b>Details</b></td> ....
Allotment of Shares under ESOP Scheme 2020 and RSU Scheme 2020
Concalls
11Feb 2026
28 Feb 2026Nov 2025
30 Nov 2025Oct 2025
31 Oct 2025Aug 2025
31 Aug 2025May 2025
31 May 2025Mar 2025
31 Mar 2025Feb 2025
28 Feb 2025Nov 2024
30 Nov 2024Aug 2024
31 Aug 2024Aug 2024
31 Aug 2024Jun 2024
30 Jun 2024Held by ETFs
13 ETFs hold indgn · sorted by weight
Held by Mutual Funds
33 schemes hold indgn · sorted by weight